Real-World Outcomes in Relapsed/Refractory Multiple Myeloma Patients Treated, or Eligible for Treatment, With Idecabtagene Vicleucel

Active, not recruiting

• Conditions: Multiple Myeloma
• Interventions: Other: Not treated; Drug: Idecabtagene vicleucel

• Registration Number: NCT06154902
• Lead Sponsor: Bristol-Myers Squibb

Brief Summary

The purpose of this study is to describe demographic and disease characteristics, treatment patterns, and clinical outcomes in the real-world setting among participants in France with relapsed/refractory multiple myeloma (RRMM) who are eligible for treatment with, or have been treated with, idecabtagene vicleucel. This study will use both prospective and retrospective data from the DESCAR-T registry database.

Detailed Description

Not available

Study Timeline

• Study Start: 2022-07-29
• Status Verified: 2023-11
• Study First Submitted: 2023-11-27
• Study First Submitted QC: 2023-11-27
• Last Update Submitted: 2023-11-27
• Study First Posted: 2023-12-04
• Last Update Posted: 2023-12-04
• Primary Completion: 2027-07-31
• Study Completion: 2027-12-31

Recruitment & Eligibility

• Status: ACTIVE_NOT_RECRUITING
• Sex: All
• Target Recruitment: 350

Inclusion Criteria

• Patients with RRMM registered in the DESCAR-T registry and eligible for treatment or treated with idecabtagene vicleucel

Exclusion Criteria

• Not registered with the social security in France

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Eligible for idecabtagene vicleucel	Not treated	Eligible for idecabtagene vicleucel treatment but not treated
Treated with idecabtagene vicleucel	Idecabtagene vicleucel	-

Primary Outcome Measures

Name	Time	Method
Overall survival	15 years

Trial Locations

Locations (1)

DESCAR-T Registry; 🇫🇷 Paris, France